QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Inks Licensing Agreement with Asterion Cannabis; Engages Monster Media to Provide IR Services

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced that it has signed an agreement with Asterion Cannabis Inc. to acquire a worldwide license to use, manufacture, distribute and sell three Health Canada approved natural health products. Per the terms of the licensing agreement, Asterion has granted PreveCeutical a non-exclusive license to use Asterion’s intellectual property to make or have made, use, distribute, sell, offer to sell and promote the products in exchange for a royalty fee payable to Asterion equaling 20% of the gross sales. The licensing agreement’s initial term is five years and is renewable for five consecutive one-year terms. In addition, PreveCeutical also announced its entrance into an agreement with Monster Media, LLC for investor relations (“IR”) services. Per the terms of the IR agreement, Monster Media will provide investor relations and marketing services to the company for a period of three months, at which time PreveCeutical has the option to renew for subsequent three-month terms. Among other marketing tools, Monster Media will host and display advertorial content supplied by the company. PreveCeutical has paid Monster Media a one-time marketing fee of $50,000 and will pay a monthly hosting fee of $2,000.

To view the full press release, visit http://ibn.fm/tzxqi

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website. For more information, visit the company’s website at www.PreveCeutical.com